# What near-adult height data add to pediatric growth research

- Article ID: research-190
- Product: IGF-1 Human (igf-1-human-625)
- Canonical page: https://heritagebiolabs.com/research-library/articles/190-what-near-adult-height-data-add-to-pediatric-growth-research
- Product collection: https://heritagebiolabs.com/research-library/products/igf-1-human
- Product page: https://heritagebiolabs.com/product/igf-1-human-625
- Reading focus: Study findings (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2025, 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are short chains of amino acids linked by peptide bonds. Some larger hormones use the same kind of bonds and carry signals that guide tissue growth. Human insulin-like growth factor 1 (IGF-1) contains 70 amino acids. Mecasermin is a recombinant medicine with the same amino-acid sequence. A patient registry examined what happened to height over years in children treated for severe growth failure. [1, 2]

No newer primary report of this exact near-adult-height analysis was identified. The study was first published online in July 2025 and appeared in a February 2026 issue. It described 102 patients who reached near-adult height during or after recombinant human IGF-1 therapy. Near-adult height is a late point in growth, when little additional height is expected. The team examined height in relation to a standard reference and explored factors associated with greater gains. [1]

Children who had started therapy before puberty and had not previously received growth-promoting treatment showed the greatest improvements as a group. The authors also found an association between a lower height score at the start and a greater gain among those patients. The measurements put growth over a year in context with growth accumulated over a much longer period. A faster rate in the first year and a higher near-adult height are related outcomes that can tell different stories. [1]

Registry data describe how people fared in clinical care. The analysis did not randomly assign treatment or when treatment began. It also focused on people who had documented near-adult height by the study cutoff. Reasons that some patients continued or stopped treatment, and incomplete measurements in later years, can influence the reported estimates. There were too few quality-of-life records to address that outcome in the analysis. [1]

The U.S. approval for mecasermin concerns growth failure in defined pediatric patients, including those with severe primary IGF-1 deficiency. The registry adds longer-term information about treated patients. It does not establish that a change in height score predicts an individual's experience or that the results apply to children with a different cause of short stature. [1, 2]

## Sources

1. Ramon-Krauel M et al. Near-Adult Height Outcomes in Patients Treated With rhIGF-1 for Severe Growth Failure: Real-World IGFD Registry Data. Journal of Clinical Endocrinology & Metabolism (publication 2025-07-08). <https://academic.oup.com/jcem/article/111/2/e500/8192872>
2. Eton Pharmaceuticals, Inc. INCRELEX (mecasermin) injection, for subcutaneous use. DailyMed (label effective 2026-05-18). <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5b2b0e1-c523-468d-9a0b-4ae4e4a8dbce>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 038 - Human Relaxin-2 and IGF-1 Human.docx; article 190; content SHA-256 87b6999bdb22af2ac667d4f0baa748c75ba5b2fedf1136ec65529217cbf1ef5a.
